BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BC Innovations | Aug 1, 2019
Distillery Therapeutics

Analogs of tumor-associated glycosphingolipids as cancer vaccines

DISEASE CATEGORY: Cancer INDICATION: Lymphoma; melanoma; lung cancer Vaccination with lipid-free analogs of tumor-associated glycosphingolipids GD2 and GD3 could treat lymphoma, melanoma and lung cancer. Mice given either the GD2- or GD3-based vaccine produced antibodies...
BC Extra | Apr 30, 2019
Clinical News

April 30 Clinical Quick Takes: Xencor, Axovant, Cell Medica

Partial hold lifted on Xencor's blood cancer bispecific  FDA lifted a partial clinical hold on a Phase I trial of XmAb14045 from Xencor Inc. (NASDAQ:XNCR), which is evaluating the bispecific antibody against CD3 and CD123...
BC Extra | Mar 14, 2019
Preclinical News

Antibody-drug conjugate against ALK could selectively treat neuroblastoma

Researchers from CHOP and Celldex showed that an antibody-drug conjugate targeting ALK selectively kills neuroblastoma cells, suggesting the ADC could have a better safety profile than marketed drug dinutuximab. Unituxin dinutuximab from United Therapeutics Corp....
BC Innovations | Feb 22, 2019
Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
BC Innovations | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
BC Innovations | Oct 19, 2018
Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
BC Week In Review | Sep 28, 2018
Clinical News

Cell Medica doses first neuroblastoma patient with NK cell therapy

Cell Medica Ltd. (London, U.K.) dosed the first patient in the open-label, U.S. Phase I GINAKIT2 trial of CMD-501 to treat relapsed or refractory pediatric neuroblastoma, which the company said marks the first use of...
BC Week In Review | Sep 28, 2018
Financial News

First-day pop for Y-mAbs after upsized $110M IPO

Cancer company Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) gained $8 (50%) to $24 on Sept. 21 after raising $110.4 million through the sale of 6.9 million shares at $16 in an IPO. BofA Merrill Lynch, Cowen, Canaccord...
Items per page:
1 - 10 of 114